Cumberland shares latest results from its Phase 2 FIGHT DMD trial

Cumberland (CPIX) Pharmaceuticals shared the latest positive results from its Phase 2 FIGHT DMD trial evaluating ifetroban, a novel oral therapy for Duchenne muscular dystrophy, DMD, heart disease, at the annual Parent Project Muscular Dystrophy, PPMD, conference in Las Vegas. These new results highlight multiple indicators of cardiac benefit with ifetroban treatment in DMD heart disease, the leading cause of death in DMD, including previously unreported pharmacokinetic findings and cardiac biomarker data that demonstrate the drug’s potential to prevent ongoing heart damage. The 12-month Phase 2 FIGHT DMD trial demonstrated that high-dose ifetroban treatment resulted in a significant 5.4% improvement in left ventricular ejection fraction compared to a control group composed of placebo-treated patients combined with propensity score-matched natural history patients. This represents a clinically meaningful difference in a progressive disease where heart function typically declines over time.